Published in Arch Mal Coeur Vaiss on July 01, 1996
[Apropos of the new classification of cardiomyopathies]. Arch Mal Coeur Vaiss (1997) 0.75
Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med (2011) 7.62
The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J (2003) 4.09
Predicting sudden death in the population: the Paris Prospective Study I. Circulation (1999) 3.80
Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in the population. Circulation (2001) 3.12
The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J (2003) 2.78
Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J (2004) 2.73
Myoblast transplantation for heart failure. Lancet (2001) 2.71
Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. Nat Genet (1995) 2.52
Long-term outcome in asymptomatic men with exercise-induced premature ventricular depolarizations. N Engl J Med (2000) 2.28
Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur Heart J (1999) 2.24
Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in genotyped children. Eur Heart J (1998) 2.20
Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation (1998) 2.04
Altered sarcoplasmic reticulum Ca2(+)-ATPase gene expression in the human ventricle during end-stage heart failure. J Clin Invest (1990) 1.94
Genotype-phenotype correlations in familial hypertrophic cardiomyopathy. A comparison between mutations in the cardiac protein-C and the beta-myosin heavy chain genes. Eur Heart J (1998) 1.79
Management of patients with heart failure in clinical practice: differences between men and women. Heart (2007) 1.73
Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart (1997) 1.72
Epidemiology of desmin and cardiac actin gene mutations in a european population of dilated cardiomyopathy. Eur Heart J (2000) 1.68
[Adherence to guidelines in CHF therapy in Germany]. Dtsch Med Wochenschr (2005) 1.58
Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. Int J Cardiol (2013) 1.55
Polyvisceral echinococcosis with cardiac involvement imaged by two-dimensional echocardiography, computed tomography and nuclear magnetic resonance imaging. Am J Cardiol (1987) 1.51
[Prognostic factors in dilated cardiomyopathies]. Arch Mal Coeur Vaiss (1988) 1.38
Inter-study variability in left ventricular mass measurement. Comparison between M-mode echography and MRI. Eur Heart J (1992) 1.38
Expanding the phenotype of LMNA mutations in dilated cardiomyopathy and functional consequences of these mutations. J Med Genet (2003) 1.37
Molecular basis of familial cardiomyopathies. Circulation (1995) 1.36
Risk stratification in chronic heart failure. Eur Heart J (1998) 1.33
Mapping of a gene for long QT syndrome to chromosome 4q25-27. Am J Hum Genet (1995) 1.29
In vivo induction of endothelial apoptosis leads to vessel thrombosis and endothelial denudation: a clue to the understanding of the mechanisms of thrombotic plaque erosion. Circulation (2004) 1.29
Left coronary artery aneurysm and anteroseptal acute myocardial infarction following blunt chest trauma. Eur Heart J (1986) 1.27
Identification of two novel mutations in the ventricular regulatory myosin light chain gene (MYL2) associated with familial and classical forms of hypertrophic cardiomyopathy. J Mol Med (Berl) (1998) 1.27
Codon 102 of the cardiac troponin T gene is a putative hot spot for mutations in familial hypertrophic cardiomyopathy. Circulation (1996) 1.18
Lack of association between polymorphisms of eight candidate genes and idiopathic dilated cardiomyopathy: the CARDIGENE study. J Am Coll Cardiol (2000) 1.18
Exclusion of cardiac myosin heavy chain and actin gene involvement in hypertrophic cardiomyopathy of several French families. Circ Res (1992) 1.16
Resting heart rate as a predictive risk factor for sudden death in middle-aged men. Cardiovasc Res (2001) 1.15
[Rupture of the interventricular septum in myocardial infarct]. Actual Cardiol Angeiol Int (Paris) (1970) 1.15
Familial hypertrophic cardiomyopathy. Microsatellite haplotyping and identification of a hot spot for mutations in the beta-myosin heavy chain gene. J Clin Invest (1993) 1.13
Exclusion of HRAS from long QT locus. Nat Genet (1994) 1.11
Skeletal actin mRNA increases in the human heart during ontogenic development and is the major isoform of control and failing adult hearts. J Clin Invest (1991) 1.11
Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in a genotyped adult population. Circulation (1997) 1.10
Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia (2005) 1.09
Characterization of a unique genetic variant in the beta1-adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy. CARDIGENE Group. J Mol Cell Cardiol (1999) 1.09
Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med (2007) 1.08
Mapping of X-linked myxomatous valvular dystrophy to chromosome Xq28. Am J Hum Genet (1998) 1.07
The influence of the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease gene mutation. J Mol Cell Cardiol (1997) 1.05
Role of endothelium-derived nitric oxide in the regulation of cardiac oxygen metabolism: implications in health and disease. Circ Res (2000) 1.03
Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey. Eur J Heart Fail (2007) 1.03
Genetic testing and genetic counselling in hypertrophic cardiomyopathy: the French experience. J Med Genet (2002) 1.01
Correlation between left ventricular hypertrophy and GAA trinucleotide repeat length in Friedreich's ataxia. Circulation (1997) 1.01
[Apropos of a case of endocarditis due to a lactobacillus]. Ann Med Interne (Paris) (1969) 1.01
An unusual familial cardiomyopathy characterized by aberrant accumulations of desmin-type intermediate filaments. Virchows Arch A Pathol Anat Histol (1981) 1.00
Factors predicting mortality in idiopathic dilated cardiomyopathy. Eur Heart J (1990) 0.99
Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J (1997) 0.99
Detection of enteroviruses in endomyocardial biopsy by molecular approach. J Med Virol (1992) 0.99
Increase in radionuclide left ventricular ejection fraction after cardioversion of chronic atrial fibrillation in idiopathic dilated cardiomyopathy. Eur Heart J (1992) 0.97
[Autologous skeletal myoblast transplantation for cardiac insufficiency. First clinical case]. Arch Mal Coeur Vaiss (2001) 0.97
A new locus for autosomal dominant dilated cardiomyopathy identified on chromosome 6q12-q16. Am J Hum Genet (2000) 0.96
[Superinfected mural thrombus in myocardial infarct]. Actual Cardiol Angeiol Int (Paris) (1966) 0.96
Double heterozygosity for mutations in the beta-myosin heavy chain and in the cardiac myosin binding protein C genes in a family with hypertrophic cardiomyopathy. J Med Genet (1999) 0.95
Intracardiac conduction defects in dystrophia myotonica. Electrophysiological study of 12 cases. Br Heart J (1980) 0.95
Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure. Eur Heart J (2000) 0.95
Danon's disease as a cause of hypertrophic cardiomyopathy: a systematic survey. Heart (2004) 0.94
Relation between QT duration and maximal wall thickness in familial hypertrophic cardiomyopathy. Heart (2002) 0.92
Familial hypertrophic cardiomyopathy. Cardiac ultrasonic abnormalities in genetically affected subjects without echocardiographic evidence of left ventricular hypertrophy. Eur Heart J (1998) 0.91
Penetrance of familial hypertrophic cardiomyopathy. Genet Couns (1997) 0.91
Bedside B-type natriuretic peptide and functional capacity in chronic heart failure. Eur J Heart Fail (2003) 0.91
Charcot-Marie-Tooth features and maculopathy in a patient with Danon disease. Neurology (2004) 0.90
Identification of a genetic risk factor for idiopathic dilated cardiomyopathy. Involvement of a polymorphism in the endothelin receptor type A gene. CARDIGENE group. Eur Heart J (1999) 0.90
Idiopathic atrial fibrillation as a risk factor for mortality. The Paris Prospective Study I. Eur Heart J (1999) 0.89
Exercise peak VO2 determination in chronic heart failure: is it still of value? Eur Heart J (1994) 0.89
Right heart failure due to an inter-atrial shunt after percutaneous mitral balloon dilatation. Eur Heart J (1989) 0.89
Endothelial dysfunction and collagen accumulation: two independent factors for restenosis and constrictive remodeling after experimental angioplasty. Circulation (1999) 0.88
Cardiomyopathy in Friedreich's ataxia: a Doppler-echocardiographic study. Eur Heart J (1992) 0.88